机构：[1]Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for LiverDisease,[2]Beijing Friendship Hospital, Capital Medical University首都医科大学附属北京友谊医院[3]Peking University Health Science Center, Beijing[4]Henan Provincial People’s Hospital[5]First Affiliated Hospital of Zhengzhou University, Zhengzhou[6]First Hospital of Lanzhou University, Lanzhou[7]First Affiliated Hospital with Nanjing Medical University, Nanjing江苏省人民医院[8]Shanghai Ruijin Hospital[9]Shanghai First People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai[10]Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院[11]Nanfang Hospital, Southern Medical University,Guangzhou[12]Second Hospital of Shandong University, Jinan[13]First Affiliated Hospital of Kunming Medical College, Kunming昆明医科大学附属第一医院[14]First Affiliated Hospital of Guangxi Medical University, Nanning[15]Fourth Military Medical University, Tangdu Hospital, Xi’an[16]People’s Hospital of Hubei Wuhan University[17]Affiliated Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan华中科技大学同济医学院附属同济医院[18]First Affiliated Hospital of Nanchang University, Nanchang[19]First Affiliated Hospital of Shanxi Medical University, Taiyuan[20]Shengjing Hospital of China Medical University, Shenyang中国医科大学盛京医院[21]First Hospital of Jilin University, Changchun[22]First Affiliated Hospital of Medical College ZheJiang University, Hangzhou浙江大学医学院附属第一医院[23]Second Xiangya Hospital of Central South University, Changsha[24]Ningxia People’s Hospital, Yinchuan[25]Southwest Hospital, Chongqing[26]West China Hospital, Chengdu四川大学华西医院[27]Second Affiliated Hospital of Harbin Medical University, Harbin[28]First Affiliated Hospital of Anhui Medical University, Hefe[29]First Affiliated Hospital of Fujian Medical University, Fuzhou, China[30]Bristol-Myers Squibb, Wallingford, Connecticut, USA
Background and AimChronic hepatitis C virus (HCV) infection is relatively frequent in China. This study investigated the clinical, demographic, and viral and host genetic characteristics that may influence disease manifestations and clinical management. MethodsIn this cross-sectional observational study, treatment-naive Han ethnic adults with recently confirmed chronic HCV infection were enrolled at 28 hospitals across China. HCV genotype and host interleukin 28B (IL28B) genotypes were determined and compared with patient demographic parameters and medical status. ResultsAmong the 997 HCV-positive patients analyzed, 56.8% were infected with HCV genotype 1b, followed in prevalence by genotypes 2, 3, and 6, with substantial regional variation. Overall, 84.1% of patients were IL28B genotype CC (rs12979860), with little regional variation. Cirrhosis was reported in 10.1% of patients and was significantly associated with hepatitis B virus coinfection, low HCV viral load, low serum alanine aminotransferase, high serum aspartate aminotransferase, diabetes, and high pickled food consumption. Medical procedures were common transmission risk factors; however, lifestyle-associated risk factors, including intravenous drug abuse and tattoos or piercings, were more common in patients with HCV genotype 3 or 6. ConclusionsMost HCV-infected Han Chinese patients were IL28B genotype CC (rs12979860). HCV genotypes varied by geographic region, and disease characteristics differed according to HCV genotype. Relatively frequent detection of advanced liver disease may reflect limitations on access to antiviral therapy, and suggests that greater awareness of factors that influence HCV-associated disease may help avoid clinical complications and improve patient outcomes.
基金：
China National
Science and Technology Major Project for Infectious Diseases
Control during the 11th Five-Year Plan Period [grant numbers
2008ZX10002-013, 2008ZX10002-012] and 12th Five-Year Plan
Period [grant number 2012ZX10002003], and from Bristol-Myers
Squibb.
第一作者机构：[1]Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for LiverDisease,
通讯作者：
通讯机构：[*1]Peking University People’s Hospital, Peking University Hepatology Institute, 11 Xizhimen South Street, Beijing 100044, China.
推荐引用方式(GB/T 7714)：
Rao Huiying,Wei Lai,Carlos Lopez-Talavera Juan,et al.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J].JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY.2014,29(3):545-553.doi:10.1111/jgh.12398.
APA：
Rao, Huiying,Wei, Lai,Carlos Lopez-Talavera, Juan,Shang, Jia,Chen, Hong...&Zhuang, Hui.(2014).Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection.JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,29,(3)
MLA：
Rao, Huiying,et al."Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection".JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 29..3(2014):545-553
